Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Apinocaltamide in Healthy Subjects
NCT03165097Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NBI-827104 in epilepsy (5 arms), sponsored by Idorsia. Primary endpoints: Incidence of treatment-emergent adverse events, Changes from baseline in vital signs and 1 more. Started Jul 2017; status: completed.
02
Drugs
NBI-827104
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03165097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165097.